Showing results (1891-1900 of 1,960) with videos related to
Sort By:
Pageof 196
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 16, 2021
Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic MalignanciesStephen M Ansell, Michael B Maris, Alexander M Lesokhin, et al.Mayo Clinic Proceedings|April 2, 2013
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013Joseph R Mikhael, David Dingli, Vivek Roy, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 3, 2018
Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin LymphomaMargaretha G M Roemer, Robert A Redd, Fathima Zumla Cader, et al.Blood Cancer Journal|August 8, 2025
Subsets of follicular lymphoma 3B have divergent outcomes: results from the prospective multicenter MER and LEO cohortsPatrizia Mondello, Brianna Negaard, Andrew L Feldman, et al.Blood|June 5, 2014
ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomesEdgardo R Parrilla Castellar, Elaine S Jaffe, Jonathan W Said, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 14, 2015
Genome-Wide Association Study of Event-Free Survival in Diffuse Large B-Cell Lymphoma Treated With ImmunochemotherapyHervé Ghesquieres, Susan L Slager, Fabrice Jardin, et al.Blood|April 3, 2015
The oncogenic transcription factor IRF4 is regulated by a novel CD30/NF-κB positive feedback loop in peripheral T-cell lymphomaRebecca L Boddicker, N Sertac Kip, Xiaoming Xing, et al.Blood Neoplasia|June 24, 2025
Outcomes for high-risk defining events in follicular lymphoma following frontline immunochemotherapyJoshua W D Tobin, Venkata A Chikatamarla, Marko Matic, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2024
Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein-Overexpressing Advanced Nonsquamous EGFR-Wildtype Non-Small Cell Lung Cancer in the Phase II LUMINOSITY TrialD Ross Camidge, Jair Bar, Hidehito Horinouchi, et al.Medrxiv : the Preprint Server for Health Sciences|June 19, 2023
Multiomic Analysis Identifies a High-Risk Metabolic and TME Depleted Signature that Predicts Early Clinical Failure in DLBCLKerstin Wenzl, Matt Stokes, Joseph P Novak, et al.Pageof 196